What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to officially report Amgen's financial results for the second quarter and first half of 2022, as detailed in the accompanying earnings press release. It also serves to inform investors about updates to the company's non-GAAP financial reporting policy.

How does Amgen present its financial results, and why?

Amgen presents both GAAP (Generally Accepted Accounting Principles) and non-GAAP financial results. The company uses non-GAAP measures, which exclude certain items like acquisition-related expenses and cost savings initiative costs, to provide investors with a better understanding of its ongoing operational performance and to facilitate period-over-period comparisons.

What is the updated non-GAAP policy, and how does it affect reported numbers?

Beginning in the first quarter of 2022, Amgen no longer excludes upfront or milestone payments for licensing/collaboration agreements and certain premiums paid on equity investments from its non-GAAP measures. While this change does not impact the Q2 2022 results, it means that previously reported non-GAAP results for periods before this change (like Q2 2021) have been restated (recast) for consistency, which could affect historical comparisons.

Where can I find the detailed financial information?

The detailed financial information, including the press release with GAAP and non-GAAP results, is furnished as Exhibit 99.1 to this 8-K filing. Exhibit 99.2 provides the recast 2021 non-GAAP financial information reflecting the updated policy.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on August 4, 2022, to furnish its second quarter 2022 earnings press release. This filing primarily provides details on the company's financial results for the three and six months ended June 30, 2022, and its financial position as of that date. Investors can find the comprehensive financial details, including GAAP and non-GAAP measures, within the press release furnished as an exhibit. The company continues to present non-GAAP financial measures to offer a more insightful view of its ongoing business performance, facilitating comparisons across periods. These non-GAAP measures exclude items such as acquisition-related expenses, costs from cost savings initiatives, and other specific income/expense items deemed outside the ordinary course of business. Importantly, Amgen has updated its non-GAAP policy starting Q1 2022, no longer excluding certain upfront or milestone payments for licensing/collaboration agreements and asset acquisitions. While this change does not impact Q2 2022 results, it does affect previously reported Q2 2021 non-GAAP figures, which have been recast for comparability.

Key Highlights

1Amgen Inc. reported its second quarter and year-to-date financial results for 2022 via an 8-K filing on August 4, 2022.
2The filing primarily consists of the company's earnings press release, providing detailed financial performance information.
3Amgen utilizes non-GAAP financial measures (e.g., non-GAAP EPS, operating income, net income) to present a clearer view of ongoing operational performance.
4Key exclusions from non-GAAP measures include acquisition-related expenses, cost savings initiative costs, and certain non-ordinary course items.
5Free Cash Flow (FCF) is also provided as a measure of liquidity.
6A significant update to Amgen's non-GAAP policy, effective Q1 2022, means certain licensing/collaboration payments and asset acquisition premiums are no longer excluded.
7Prior period (2021) non-GAAP results have been recast to align with the updated policy, impacting comparability for those periods.

AMGEN INC 8-K Report, Financial Results (Aug 4, 2022)

Summary

Key Highlights

Frequently Asked Questions